Launch of a share buyback program by Ipsen

On June 2, 2025, Ipsen announced the launch of a share buyback program, representing a maximum of 600,000 shares, or approximately 0.72% of the share capital. This buyback is intended to support the employee share grant plan. The operation will extend over a maximum period of six months, pursuant to the authorization obtained at the Combined General Meeting of Shareholders on May 21, 2025.

Ipsen, listed on Euronext Paris and through an American Depositary Receipt program in the United States, operates in the biopharmaceutical sector with a focus on Oncology, Rare Diseases and Neuroscience.